Recent Quotes (30 days)

You have no recent quotes
chg | %

Cynapsus Therapeutics Inc  

(Public, CVE:CTH)   Watch this stock  
Find more results for CTH
Nov 27 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.38 - 1.51
Open     -
Vol / Avg. 0.00/303,419.00
Mkt cap 98.66M
P/E     -
Div/yield     -
EPS -0.14
Shares 79.56M
Beta 0.81
Inst. own     -
Nov 12, 2015
Q3 2015 Cynapsus Therapeutics Inc Earnings Release

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -10.31% -99.71%
Return on average equity -10.73% -134.69%
Employees 6 -
CDP Score - -


828 Richmond St W
+1-416-7032449 (Phone)
+1-416-7038752 (Fax)

Website links


Cynapsus Therapeutics Inc. is a Canada-based clinical-stage, specialty pharmaceutical company. The Company is engaged in developing a sublingual thin filmstrip to manage OFF episodes associated with Parkinson’s disease. The Company's drug candidate is APL-130277, which is a reformulation of apomorphine. The drug is an approved acute drug in the United States, Europe, Japan and other countries. The Company completed a CTH-105 Phase II clinical trial comprising approximately 16 people with Parkinson's disease.

Officers and directors

Rochelle E. Stenzler Independent Chairman of the Board
Age: 52
Anthony Giovinazzo President, Chief Executive Officer, Director
Andrew Williams Chief Financial Officer, Chief Operating Officer
Thierry Bilbault Executive Vice President - Chemistry, Manufacturing and Controls, Chief Scientific Officer
Kristen Galfetti Vice President of Investor Relations and Corporate Communications
Jordan Dubow M.D. Vice President - Medical Affairs
Albert Agro Chief Medical Officer
Tomer Gold Independent Director
Ronald G. Hosking Independent Director
Age: 70
Tamar D. Howson Independent Director
Age: 67